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Abstract: In this paper, we present novel bioactivity for barettin isolated from the marine 
sponge Geodia barretti. We found that barettin showed strong antioxidant activity in 
biochemical assays as well as in a lipid peroxidation cell assay. A de-brominated synthetic 
analogue of barettin did not show the same activity in the antioxidant cell assay, indicating 
that bromine is important for cellular activity. Barettin was also able to inhibit the secretion 
of the inflammatory cytokines IL-1β and TNFα from LPS-stimulated THP-1 cells. This 
combination of anti-inflammatory and antioxidant activities could indicate that barettin has 
an atheroprotective effect and may therefore be an interesting product to prevent 
development of atherosclerosis. 
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It is a well-known fact that sponges are rich sources of bioactive compounds. Barettin  
(cyclo-[6-bromo-8-en-tryptophan]-arginine]) was first isolated and described in 1986 [1] from the 
marine sponge Geodia barretti and in 2002, Sölter et al. published data suggesting a slight structure 
modification of the originally proposed molecule [2]. This revised structure (Figure 1(1)) was later 
confirmed by Johnson et al., when they successfully synthesized barettin [3].  
Figure 1. Barettin (1) and debromobarettin (2). 
  
1 2 
Previously, barettin was proven to have anti-fouling properties [4–7] and these properties are 
thought to be caused by the serotonin-like structure (Figure 1(1)) [8,9]. The identification of barettin 
from G. barretti collected outside Northern Norway was the result of the antioxidant screening project 
at MabCent-SFI [10]. The compound showed strong antioxidant activities in biochemical assays, and 
we decided to further investigate the possibility of new biological activities of this molecule. These 
studies included cellular antioxidant assays and anti-inflammatory assays. As the antioxidant defence 
system and the immune system are closely linked in diseases like arthritis, diabetes, asthma and 
coronary heart diseases, we were interested in examining whether barettin also has an anti-inflammatory 
effect. Several natural products which have combined antioxidant and anti-inflammatory effects have 
previously been described, especially from fruits and plants [11,12]. Of the more well-known are 
fucoxanthin and resveratrol. Fucoxanthin exerts many effects, including radical scavenging and 
inhibition of several inflammatory cytokines and mediators [13] whereas resveratrol induces 
antioxidant enzymes as well as reduce atherosclerotic lesions [14].  
The purpose of this work was to study the antioxidant and anti-inflammatory effects of barettin. 
Originally, less than 13 mg barettin was isolated from G. barretti. In order to perform bioactivity 
studies and confirm the structure, we synthesized barettin and also a de-brominated analogue  
(Figure 1(2)), which were both tested in biochemical and cellular assays. Thus, in this paper we will 
present novel antioxidant and anti-inflammatory activities for barettin and debromobarettin. 
2. Results and Discussion 
2.1. Bioactivity Testing 
2.1.1. Antioxidant Activity 
We used the biochemical assays FRAP (ferric reducing antioxidant power) and ORAC (oxygen 
radical absorbance capacity) to obtain an indication of the antioxidant potential of barettin and the 
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synthetic de-brominated analogue. A dose-response activity was observed for both compounds  
(Figures 2 and 3). At a concentration of 30 μg/mL (71.6 μM) barettin had a FRAP value of 77 μM 
trolox equivalents (TE) whereas the ORAC value was 5.5 μM TE.  
Figure 2. Both barettin and the debromobarettin act in a dose-dependent manner in the 
oxygen radical absorbance capacity (ORAC) assay to protect fluorescein from degradation 
(n = 2). 
 
Figure 3. The antioxidant effect of barettin and debromobarettin tested in the ferric 
reducing antioxidant power (FRAP) assay. Both molecules reduce iron in a dose-dependent 
manner (n = 2). 
 
Biochemical assays are fast, cost-effective and can offer useful information of antioxidant activity. 
Cellular assays can offer more biological relevant information since they take into account the 
bioavailability and metabolism of the tested compound [15,16]. To further explore the antioxidant 
potential of barettin we tested the compounds in two cellular antioxidant assays using HepG2 cells, a 
human liver hepatocellular carcinoma cell line often used to study the antioxidant effect of natural 
products [17]. Murakami et al. for instance used HepG2 to study the effect of catechins on cellular 
Mar. Drugs 2013, 11 2658 
 
 
antioxidant systems [18] and Alia et al. showed that quercetin could protect these cells from oxidative 
stress by tert-butyl hydroperoxide [19]. 
We used the cellular antioxidant activity assay (CAA, Figure 4) and the cellular lipid peroxidation 
antioxidant activity (CLPAA, Figure 5) assays [20,21] to measure the intracellular reactive oxygen 
species (ROS) and the lipid membrane antioxidant activity, respectively. None of the molecules had 
any effect in the CAA assay (Figure 4). Barettin gave a 55% reduction in lipid peroxidation compared 
to the control in the CLPAA assay (Figure 5), whereas debromobarettin did not show any activity.  
Figure 4. Cellular Antioxidant Activity (CAA) results for barettin and debromobarettin. 
Neither compound reduced the intracellular oxidation in HepG2 cells. Luteolin (10 μM) 
was used as a comparative control. Results are normalized to a positive control  
2,2′-Azobis(2-methylpropionamidine) dihydrochloride (AAPH) (n = 3). 
 
Figure 5. Cellular Lipid Peroxidation Antioxidant Activity (CLPAA) results for barettin 
and debromobarettin. Barettin acts in a dose-dependent manner to reduce lipid peroxidation 
in HepG2 cells. This effect was not seen with the de-brominated molecule. Butylated 
hydroxytoluene (BHT; 10 μM) was used as a comparative control. Results are normalized 
to positive control with cumene hydroperoxide (CumOOH) (n = 3). 
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The cellular assays give more information about the antioxidant activity where the CAA indicates 
the overall oxidative status of the cell by monitoring the decomposition of the water-soluble probe 
2′,7′-Dichlorofluorescin diacetate (DCFH-DA) into the fluorescent dichlorofluorescein (DCF) [20,22]. 
The CLPAA assay on the other hand detects antioxidants preventing lipid peroxidation in cellular 
membranes by monitoring the increase of a green fluorescence product produced by the lipophilic 
probe C-11-BODIPY after addition of cumene hydroperoxide (CumOOH) [21]. 
The lack of response in the CAA assay and the inhibition observed in the CLPAA assay indicates 
that barettin is not able to prevent formation of the fluorescent DCF by reactive oxygen species (ROS) 
but inhibits radicals from oxidizing the C-11-BODIPY and membrane lipids.  
The barettin molecule has a polar arginine and a non-polar brominated tryptophan end  
(Figure 1(1)) [2,3]. The bromine present in barettin is the only feature distinguishing it from the  
de-brominated synthetic analogue (Figure 1). Several research groups have proved that halogens are 
important for cellular antioxidant activity such as Gentry et al. who studied the effect of inserting 






]) [23]. They observed that the 
lipophilicity and the cell membrane solubility of the CNS-acting drug are dependent on halogenation. 
Also Gerebtzoff et al. used parameters like surface activity and permeability coefficient to show that 
halogenation improves the drug membrane binding and diffusion in general [24]. Thus we believe that 
the absence of bromine in the de-brominated analogue reduces the bioavailability and explains the lack 
of inhibition of the lipid peroxidation seen in the HepG2 cells used in the CLPAA assay.  
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) can oxidize lipids in  
low-density lipoprotein (LDL) and cell membranes and lead to conditions like atherosclerosis and 
chronic inflammation [25,26]. The oxidized lipids are recognized by pattern recognition receptors on 
immune cells and elicit an immune response by attracting monocytes [27]. In atherosclerosis, foam cell 
formation initiated by activated macrophages by uptake of oxidized LDL generate plaque development 
in the blood vessel intima [25]. In this scenario, antioxidants are thought to prevent LDL and cell 
membrane lipids from being oxidized and thus inhibit development of oxidative stress related diseases, 
including plaque development and atherosclerosis [28].  
2.1.2. Anti-Inflammatory Activity 
Atherosclerosis is recognized as a chronic inflammatory disease where oxidative stress is involved 
in the onset and progression [29]. We wanted to study whether barettin could also have an  
anti-inflammatory effect in addition to the lipid peroxidation inhibition observed, making it highly 
interesting as a possible atheroprotective compound. Using the human acute monocytic leukemia cell 
line (THP-1) and ELISA, we monitored the tumor necrosis factor α (TNFα) and interleukin-1β  
(IL-1β) production. We found a dose-dependent inhibition of IL-1β production with increasing 
concentration of barettin (up to 100 μg/mL, Figure 6). At concentrations ranging from 50 to 100 μg/mL 
TNFα secretion was also inhibited (data not shown).  
As the anti-inflammatory cell system is very sensitive to endotoxin contaminants, LPS present in 
the environment as endotoxin can in even small amounts affect any bioassay [30,31]. It is therefore 
essential to avoid such contamination in immune assays. In order to obtain endotoxin-free samples we 
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used polymyxin B based gel-packed columns to remove pyrogens. The pyrogen-free sample was then 
used in the anti-inflammatory assay.  
Figure 6. Interleukin-1β secretion from THP-1 cells were inhibited by barettin in a  
dose-dependent manner (n = 3). 
 
2.2. Cytotoxicity 
The previously reported anti-fouling properties of barettin and the presented cellular effects could 
be caused by a general toxicity with the bromine as a cytotoxic “inducer”. Hepatocytes are good 
models for studying toxicity since the liver is the primary site for drug metabolism and 
biotransformation [32,33]. In addition to the hepatocyte cell line HepG2 we also included normal lung 
fibroblasts (MRC-5) and THP-1 cells when testing for cytotoxicity.  
Cytotoxicity was tested using the CellTiter 96 AQueous One Solution Assay (Promega). In the 
CAA and CLPAA assays the cells were exposed to the test compounds for 1 h before washing. Thus a 
2 h exposure on HepG2 cells should detect whether barettin and/or debromobarettin are likely to cause 
cell death and false results in these assays. The three cell lines were also exposed to the compounds for 
24 h in a separate testing. This would reveal more long-term damage or whether any toxicity was 
caused by something other than membrane lysis. As can be seen from Figure 7, neither barettin nor 
debromobarettin were toxic to the HepG2 after 24 h in the concentrations tested. Toxicity was neither 
detected in THP-1 (after 6 and 24 h) nor MRC-5 cells (data not shown).  
Barettin was also tested for cytotoxicity on HepG2 and MRC-5 after 72 h exposure (data not 
shown), and the compound did not show cytotoxicity until concentrations reached 100 µg/mL,  
a concentration well above the maximum of 30 μg/mL used in the CAA/CLPAA assays. 
3. Experimental Section  
3.1. Purification, Isolation and Identification 
The sponge was collected by bottom trawling at 390 m depth in the Barents Sea. The lyophilized 
material was extracted twice with ultrapure water (2 × 1000 mL) at 4 °C and centrifuged at 4500× g 
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and 5 °C for 30 min before the pellet was freeze dried. The lyophilized pellet was extracted twice with 
1000 mL dichloromethane:methanol (1:1, v:v) at 4 °C and subsequently filtered through a Whatman 
No3 filter. The filtrate was reduced to an orange oily liquid at 40 °C and reduced pressure in a rotary 
evaporator giving 9 g of organic extract. The organic extract was further chromatographed on a  
HP20-resin using a solvent step-gradient system of 5%, 25%, 50% and 75% aqueous methanol and two 
last steps of 100% methanol and 100% acetone. The fraction eluted with 50% methanol was reduced to 
dryness and dissolved in 1 mL 50% aqueous acetonitrile. Barettin was isolated using a Waters HPLC 
auto-purification system equipped with a Waters XTerra C18 column (10 × 300 mm, 10 µm) and 
eluted with a gradient from 25% to 35% of acetonitrile (ACN) and water, both containing 0.1% formic 
acid and at a flow rate of 6 mL/min. Two isomers of barettin eluted as two peaks giving 12.9 and 3.9 mg 
pure compound (retention time 5.1 and 6.3, respectively). High-resolution ESIMS gave m/z 419.0830 
[M + H]
+
, as the calculated m/z for C17H19BrN6O2 ([M + H]
+
) is 419.0826. 
Figure 7. Results from cytotoxicity testing of barettin and debromobarettin using HepG2 
cells. Results are expressed as percent survival after 24 h exposure (n = 2). 
 
3.2. Synthesis 
Barettin and debromobarettin were synthesized according to the published procedure for barettin [3]. 




, Nω′-bis(tert-butoxycarbonyl)-arginine was used as 
starting material (Bachem, Switzerland). The 
1
NMR and HRMS data were in agreement with 
published data [2,5]. The crude synthetic products were purified on a Waters HPLC auto-purification 
system using a Waters XTerra C18 column (10 × 300 mm, 10 µm) and ACN and water (both 
containing 0.1% formic acid) as mobile phase at a flow rate of 6 mL/min. Barettin was isolated using a 
gradient from 20% to 40% ACN over 10 min (Rt 7.0 min), and debromobarettin was isolated using a 
gradient from 15% to 25% ACN over 15 min (Rt 7.2 min). 
3.3. Biochemical Assays 
FRAP assay. Reagents were prepared according to Benzie and Strain [34] and carried out in a DTX 
880 Multimode Detector (Beckman Coulter, CA, USA) at 595 nm. Trolox (Sigma-Aldrich, St. Louis, 
Mar. Drugs 2013, 11 2662 
 
 
MO, USA) was used to prepare the standard curve (0–250 μM; working concentration). The FRAP 
reagent (TPTZ (2,4,6-Tris(2-pyridyl)-s-triazine): Sigma-Aldrich; Fe: Merck, Darmstadt, Germany) 
was prepared daily. The assay was carried out in clear 96-well plates with 20 μL sample and 150 μL 
FRAP-reagent added to each well in duplicates. Water was used as a blank. Samples were incubated at 
37 °C for 30 min before reading the plate. The blank was subtracted from each sample and a standard 
curve was created from the average absorbance of the duplicated trolox samples. The equation 
generated from the standard curve was used to calculate the trolox equivalents (TE) from each sample. 
Results were expressed as μM TE.  
ORAC assay. The method has been modified from Huang et al. [35]. The assay was carried out in 
black 96-well plates (Nunc) using a Victor3 Plate Reader (Perkin Elmer, MA, USA) at 37 °C 
(excitation 486 nm, emission 520 nm). All reagents were dissolved in 75 mM phosphate buffer  
(PB, pH 7.4). Diluted concentrations of barettin and debromobarettin were added in duplicates 
followed by addition of 125 μL fluorescein (52 nM final concentration, Sigma-Aldrich). After a  
15 min incubation at 37 °C, 60 μL AAPH (2,2′-Azobis(2-methylpropionamidine) dihydrochloride; 
Sigma-Aldrich) was quickly added to each sample (44 mM final concentration). Fluorescence was 
recorded 25 times at 37 °C with a 70 s. delay between repeats. Trolox (0–25 μM working 
concentration) was included in each run to make a standard curve. PB was used as a blank and for the 
0 μM Trolox sample. Area under the curve (AUC) was calculated by subtracting the AUCBlank values. 
A standard curve was created using the trolox values and trolox equivalents of the samples were 
calculated from the resulting equation. Results were expressed as μM TE. 
3.4. Cellular Assays 
HepG2 and MRC-5 cells were grown in MEM Earle’s medium (F0325) supplemented with 
gentamycin (10 μg/mL), non-essential amino acids (1%), sodium pyruvate (1 mM), L-alanyl-L-glutamine 
(2 mM) and fetal bovine serum (FBS, 10%) and incubated at 37 ºC with 5% CO2. Media and 
supplements were from Biochrom (Berlin, Germany). THP-1 cells were grown in RPMI-1640 
(Biochrom) supplemented with gentamycin and FBS and incubated at 37 °C with 5% CO2.  
To differentiate the monocytes into macrophages, 50 ng/mL phorbol 12-myristate 13-acetate (PMA) 
(Sigma Aldrich) was added.  
3.4.1. Cellular Lipid Peroxidation Antioxidant Activity (CLPAA) Assay 
Approximately 80,000 HepG2 cells per well were seeded in black 96 well plates with clear bottom 
(Corning, NY, USA) and incubated overnight. Cells were washed with PBS between additions of new 
reagents. Total reaction volume was 100 μL. All incubations were carried out at 37 °C with 5% CO2. 
The cells were labelled with C11-BODIPY (Invitrogen, Eugene, OR, USA) for 30 min and incubated 
for 1 h with various concentrations of the test compounds. Cumene hydroperoxide (CumOOH,  
Sigma-Aldrich) was added to initiate lipid peroxidation and the plate was immediately installed in a 
Victor3 Plate Reader. Both red (590/7 nm (excitation), 632/45 nm (emission)) and green (485/14 nm, 
520/10 nm) fluorescence were recorded. Percent inhibition was calculated relative to the positive 
control (CumOOH without test compound).  
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3.4.2. Cellular Antioxidant Activity (CAA) Assay 
The CAA assay was modified from Wolfe and Liu [20]. HepG2 cells were seeded and grown as 
described for the CLPAA assay. Cells were washed with PBS between additions of new reagents. 
Total reaction volume was 100 μL. The incubations were at 37 °C, 5% CO2. Cells were then incubated 
with 25 μM DCFH-DA (Sigma-Aldrich) and 20 μL test compound for 1 h. After incubation, 600 μM 
AAPH was added and the plate immediately placed in in a Victor3 Plate Reader (excitation/emission; 
485/520 nm). The plate was incubated for 1 h before the second reading. Results are presented as 
relative values compared to the AAPH control.  
3.4.3. Cytotoxicity 
Cytotoxicity was studied in HepG2, MRC-5 cells (normal human lung fibroblasts) and THP-1 cells 
for 2 h (HepG2), 6 h (THP-1) and 24 h (HepG2, MRC-5 and THP-1). For the 2 h study, 80,000 HepG2 
cells were seeded per well. For the 24 h study, 50,000 HepG2 cells, 7500 MRC-5 cells and 10,000 
THP-1 cells were used. HepG2 and MRC5 were grown over night, then washed with PBS and added 
50 μL test compound at various concentrations diluted in MEM Earle’s supplemented as above but 
without FBS. THP-1 cells were grown as described in the immune assay. After incubation, 10 μL of 
CellTiter 96
®
 AQueous One Solution Reagent (Promega, Madison, WI, USA) was added and plates 
were then incubated further for 1 h. Absorbance was measured at 485 nm in a DTX 880 Multimode 
Detector. Results were calculated as % survival compared to negative (assay media) and positive 




 THP-1 cells supplemented with 50 ng/mL PMA were seeded in 96 well plates 
and incubated at 37 °C, 5% CO2 for 48 h. The cells were controlled after 24 h by microscopy to make 
sure they had started to differentiate. After 48 h, the cells were washed and new RPMI (w/o PMA) 
added before 24 h incubation. 
The cells were then added 90 µL fresh medium and 10 µL test compound at various concentrations 
in duplex. Controls were included in every test run. After incubation for 1 h, all samples except 
negative cell controls were incubated with 1 ng/mL lipopolysaccharide (LPS; end concentration) for 
another 6 h at 37 °C. The reactions were stopped by freezing the plates at −80 °C immediately  
after incubation.  
One day prior to the ELISA testing of IL-1β and TNFα secretion, MaxiSorp 96F-well plates (Nunc) 
were coated with 2 µg/mL capture antibody (eBioscience, San Diego, CA, USA) and placed in the 
refrigerator overnight.  
Between every step, plates were washed with TBS (pH 7.4, with 0.05% Tween-20). All incubations 
were at room temperature with shaking. A volume of 200 µL blocking buffer (TBS w/2% BSA) was 
added to the plates and incubated for 1 h. TNFα samples were diluted 1:4 or 1:10 and IL-1β samples 
diluted 1:2. Standard concentrations of IL-1β and TNFα were added to each plate before incubation for 
2 h. Biotin coupled anti-human antibody (eBioscience) was diluted in assay diluent (TBS with 1% BSA) 
to 3 µg/mL and added to each well and incubated for 1 h. Diluted ExtrAvidin
®
-Alkaline Phosphatase 
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(Sigma-Aldrich) was added and plates incubated for 30 min. 100 μL pNPP substrate (Sigma-Aldrich,  
1 mg/mL in 1 M diethanolamin buffer pH 9.8) was added to each well, incubated for 45 min and 
results read at 405 nm. 
3.4.5. Endotoxin Removal 
We used Detoxi-Gel Endotoxin Removing Columns from Thermo Scientific (Waltham, MA, USA) 
according to the manufacturers’ description. Synthesized barettin was dissolved in DMSO to  
100 mg/mL. The sample was further diluted in pyrogen-free water to 5 mL. After regeneration and 
equilibration of the column the sample was applied and the flow-through collected. The sample was 
then freeze-dried overnight. The test tube with barettin was weighed before and after elution to 
estimate the sample weight.  
4. Conclusions 
Compounds with combined antioxidant and anti-inflammatory properties are of interest for 
treatment of for instance cardiovascular diseases such as atherosclerosis. Atherosclerosis is a 
widespread disease, especially in the western world and today there are no therapeutic treatment 
directly targeting this disease except cholesterol lowering drugs (statins). We found that barettin 
possess both anti-inflammatory and antioxidant properties making it a candidate for further studies as 
an atheroprotective compound. We also found interesting differences between barettin and 
debromobarettin, indicating that bromine could be important for in vivo activity of the compounds. 
Both compounds are active in the biochemical antioxidant assays but only barettin is active in the 
cellular CLPAA assay where it reduced lipid peroxidation in HepG2 cells. Barettin also inhibited  
IL-1β and TNFα reduction in THP-1 immune cells. Based on these results barettin is interesting as a 
lead compound for further structure-activity studies to elucidate the modes of action and any  
clinical potential. 
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